Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Revenues:
Biocatalyst product sales	$ 13,064	$ 20,423	$ 35,924
Biocatalyst research and development	14,945	6,868	49,977
Revenue sharing arrangement	7,298	4,631	150
Government awards	0	0	2,247
Total revenues	35,307	31,922	88,298
Costs and operating expenses:
Cost of biocatalyst product revenues	9,726	14,554	30,647
Research and development	22,755	31,606	56,785
Selling, general and administrative	21,937	26,908	31,379
Total costs and operating expenses	54,418	73,068	118,811
Loss from operations	(19,111)	(41,146)	(30,513)
Interest income	18	60	252
Other expense	(234)	(304)	(326)
Loss before income taxes	(19,327)	(41,390)	(30,587)
Provision for (benefit from) income taxes	(256)	(87)	270
Net loss	$ (19,071)	$ (41,303)	$ (30,857)
Net loss per share of common stock, basic and diluted (dollars per share)	$ (0.50)	$ (1.08)	$ (0.84)
Weighted average common shares used in computing net loss per share of common stock, basic and diluted (shares)	38,209	38,231	36,768